[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"knee-osteoarthritis-oa\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:knee-osteoarthritis-oa":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,73,99,122,143,163,193,216,238,265,300,325],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100629973","phase-3-a-research-study-investigating-how-well-the-medicine-nnc0487-0111-helps-people-with-excess-body-weight-and-knee-osteoarthritis-lose-weight-and-reduce-pain-100629973",false,"NCT07481630","A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","Efficacy and Safety of NNC0487-0111 s.c. Once-weekly in Participants With Overweight or Obesity, and Knee Osteoarthritis (AMAZE 5)","AMAZE 5","Key inclusion Criteria:\n\n* Male or female (sex at birth).\n* Age 18 years or above at the time of signing the informed consent.\n* Clinical diagnosis of knee osteoarthritis (American College of Rheumatology criteria) with radiographic changes (Kellgren Lawrence (KL) grades 2 to 3 as per central reading) in target knee. Target knee joint is defined as most symptomatic knee at screening. If pain in knees is equal, the target knee joint will be the dominant leg.\n* Symptomatic knee OA with first appearance of pain in the target knee more than (\\>) 90 days prior to screening and pain in the target knee for \\> 15 days over the prior 30 days.\n* Willingness to complete a 72-hour washout period of analgesics before all visits involving WOMAC Osteoarthritis Index NRS 3.1 (24-hour) (WOMAC) questionnaire (acetaminophen 4 gram (g)\u002Fday is allowed as rescue medication up until 24 hours before those visits).\n\nExclusion Criteria:\n\n* Glycated haemoglobin more than or equal to (≥) 6.5% \\[(48 millimoles per mole (mmol\u002Fmol)\\] as measured by the central laboratory at screening.\n* History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.\n* Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1\u002Fgastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.\n* Any joint prosthesis or joint replacement in target knee.\n* Arthroscopy or injections into target knee within the last 90 days prior to screening.\n* Any other joint disease in target knee including gout and pseudogout.","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight and knee osteoarthritis. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.",[27,28],"Obesity","Knee Osteoarthritis (OA)","RECRUITING","2026-06-01",{"date":32,"type":33},"2026-06-02","ACTUAL",{"date":35,"type":33},"2026-04-13",{"date":37,"type":21},"2028-08-14",{"name":39,"class":40},"Novo Nordisk A\u002FS","INDUSTRY",82,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":52,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100576143","creation-of-a-prospective-data-collecting-registry-for-genicular-artery-embolization-for-arthritis-100576143","NCT06781463","Creation of a Prospective Data Collecting Registry for Genicular Artery Embolization for Arthritis","Creation of a Prospective Data Collecting Registry for Genicular Artery Embolization for Arthritis (GAE)","GAE","Inclusion Criteria:\n\n* Patients aged \\>=18\n* Bilateral or unilateral knee pain attributed to knee osteoarthritis (KOA). For bilateral KOA patients, the more severe knee will be permitted inclusion to the registry\n* Grade 1-3 Osteoarthritis as diagnosed on standing weight-bearing knee radiographs per the Kellen-Lawrence Grading scale\n* Knee pain \\>6 months refractory to conservative medical management (Nonsteroidal anti-inflammatory drugs, acetaminophen, etc.)\n* Not eligible for surgical knee replacement or patient's personal preference to undergo Genicular Artery Embolization (GAE) for reasons such as minimally invasiveness of GAE\n\nExclusion Criteria:\n\n* Active malignancy\n* Active infection of the affected knee\n* Platelets \\\u003C50,000\u002FuL, INR \\>2.0 (unless on anticoagulation that can be reversed or performing radial\u002Fpedal access without reversal)\n* Corticosteroid injection of the affected knee within 3 months of enrollment\n* Rheumatoid arthritis or other seronegative arthropathy\n* Previous surgery (excluding arthroscopy) of the affected knee\n* Grade 4 per Kellgren-Lawrence Grading Scale of the affected knee\n* Pregnancy or expected pregnancy\n* Glomerular Filtration Rate (GFR) \\\u003C30\n* Anaphylactic reaction to iodinated contrast\n* Moderate to severe pain in other lower limb joints\n* Body weight \\>400 lbs. (prohibiting safe angiography)\n* Peripheral arterial disease of the treated extremity (Rutherford Grade 2 or greater)",{"count":51,"type":21},100,"1 Year","OBSERVATIONAL","The goal of this study is to create a prospective registry (\\\u003C100 patients) to show the effectiveness of the genicular artery embolization procedure overtime in reducing bilateral or unilateral osteoarthritic knee pain as measured by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score.",[56,57,28],"Knee Osteoarthritis","Knee Osteoarthritis (Knee OA)",[59,60,61],"knee pain","knee replacement alternative","knee arthritis","2026-05-12",{"date":64,"type":33},"2026-05-13",{"date":66,"type":33},"2023-10-01",{"date":68,"type":21},"2028-10-01",{"name":70,"class":71},"University of Chicago","OTHER",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":72},"100631880","tourniquet-vs-no-tourniquet-technique-in-total-knee-arthroplasty-at-the-university-hospital-of-the-west-indies-100631880","NCT07506434","Tourniquet Vs. No-Tourniquet Technique in Total Knee Arthroplasty at the University Hospital of the West Indies","Is Routine Tourniquet Use Still Warranted? A Randomized Controlled Equivalence Trial Comparing Tourniquet Vs. No-Tourniquet Technique in Total Knee Arthroplasty at the University Hospital of the West Indies","Inclusion Criteria:\n\n* • Age ≥ 18 years.\n\n  * Clinical and radiographic diagnosis of knee osteoarthritis requiring primary unilateral Total Knee Arthroplasty.\n  * Medically fit for elective surgery (typically ASA I-III).\n  * Able to provide informed consent.\n\nExclusion Criteria:\n\n* • Revision TKA or bilateral simultaneous TKA.\n\n  * Preexisting coagulopathy or active anticoagulation that cannot be perioperatively managed per protocol.\n  * Known allergy or contraindication to tranexamic acid.\n  * Active infection or immunosuppression.\n  * Severe peripheral vascular disease in the operative limb.\n  * BMI \\> 45 kg\u002Fm²\n  * Inability to provide informed consent or comply with follow-up",{"count":81,"type":21},30,[83],"NA","The goal of this clinical trial is to determine whether performing total knee replacement surgery (total knee arthroplasty, TKA) without a tourniquet is clinically equivalent to performing the procedure with a tourniquet in adults with symptomatic knee osteoarthritis.\n\nA tourniquet is commonly used during surgery to reduce bleeding and improve the surgeon's view. However, some studies suggest it may be associated with certain complications. It is currently unclear whether using a tourniquet meaningfully changes outcomes compared to not using one. This study aims to assess whether both approaches result in similar outcomes within a clinically acceptable range.\n\nThe main question this study aims to answer is:\n\nIs total blood loss during surgery equivalent between TKA performed with a tourniquet and TKA performed without a tourniquet, within a predefined margin of ±100 mL?\n\nAdditional questions include:\n\nAre surgical field quality, postoperative pain, functional recovery, and complication rates comparable between the two techniques?\n\nResearchers will compare:\n\nTKA performed with a pneumatic tourniquet TKA performed without a tourniquet\n\nto determine whether outcomes between the two approaches are equivalent rather than whether one is superior to the other.\n\nParticipants will:\n\nBe randomly assigned to one of the two surgical groups using a computer-generated process Undergo standard total knee replacement surgery and routine perioperative care Have blood loss assessed during and after surgery Be monitored for pain, recovery of function, wound healing, and complications during hospital stay and follow-up visits\n\nThis study is designed as a randomized controlled equivalence trial to determine whether both surgical approaches produce comparable outcomes within clinically acceptable limits, in a standardized local setting.",[28,86],"Total Knee Anthroplasty",[88],"tourniquet use","NOT_YET_RECRUITING","2026-03-27",{"date":92,"type":33},"2026-04-01",{"date":94,"type":21},"2026-06",{"date":96,"type":21},"2027-09",{"name":98,"class":71},"The University of The West Indies",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":17,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":72},"100630692","cross-education-from-unilateral-strength-and-balance-training-in-older-adults-with-bilateral-knee-osteoarthritis-100630692","NCT07490977","Cross-Education From Unilateral Strength and Balance Training in Older Adults With Bilateral Knee Osteoarthritis","Cross-Education of Combined Unilateral Strength and Balance Training on Motor Function in Older Adults With Bilateral Knee Osteoarthritis","Inclusion Criteria:\n\n* age 60-80 years,\n* bilateral knee osteoarthritis of grade II-III according to the Kellgren-Lawrence classification\n\nExclusion Criteria:\n\n* acute lower extremity injuries in the past year,\n* taking nonsteroidal anti-inflammatory drugs within the past month,\n* involvement in physical therapy within the past 6 months,\n* undergoing intra-articular injections and\u002For knee surgery within the past year,\n* rheumatoid arthritis, septic arthritis, uncontrolled diabetes, other systemic inflammatory and autoimmune diseases, and severe cardiovascular, renal, and hepatic comorbidities","60 Years","80 Years",{"count":109,"type":21},45,[83],"Kinesitherapy is one of the main tools in the rehabilitation of knee osteoarthritis, but is often limited due to pain, reduced functionality, and fear of falling in older adults. This study will, through three sub-studies, examine the effects of unilateral training programs on strength, movement control, balance, and pain in the contralateral leg, as well as on functionality, fall risk, and kinesiophobia in older adults with bilateral knee osteoarthritis through three sub-studies. A total of 45 participants (aged 60-80 years) with bilateral knee osteoarthritis will be randomly assigned to one of three groups: 1. combined unilateral strength and balance training; 2. unilateral balance training; 3. unilateral strength training. Strength will be measured with maximal voluntary contraction, balance using a single leg stance test on an unstable surface, movement control with an active joint position reproduction test, and functionality using the six-minute walk test and the Western Ontario and McMaster Osteoarthritis Index questionnaire. Pain will be assessed with the Visual Analog Scale and the Intermittent and Constant Osteoarthritis Pain questionnaire, fall risk with the Timed Up and Go test and the Falls Efficacy Scale-International questionnaire, and kinesiophobia using the TAMPA questionnaire. This study will expand knowledge on cross-transfer and its effects on symptoms in the rehabilitation of older adults with bilateral knee osteoarthritis.\n\nThis research is a part of a doctoral thesis conducted under the supervision of assoc. prof. Tatjana Trošt, PhD.",[28],"2026-03-18",{"date":115,"type":33},"2026-03-24",{"date":117,"type":21},"2026-09",{"date":119,"type":21},"2027-12",{"name":121,"class":71},"University of Zagreb",{"id":123,"slug":124,"hasResults":11,"nctId":125,"briefTitle":126,"officialTitle":127,"acronym":4,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100629884","proprioception-kinesiophobia-and-functional-recovery-after-gonarthrosis-surgery-100629884","NCT07480473","PROPRIOCEPTION, KINESIOPHOBIA AND FUNCTIONAL RECOVERY AFTER GONARTHROSIS SURGERY","THE RELATIONSHIP BETWEEN PROPRIOCEPTION, KINESIOPHOBIA, BALANCE, AND SENSORY PROFILE WITH FUNCTIONAL RECOVERY AFTER GONARTHROSIS SURGERY","Inclusion Criteria:\n\n* The study included individuals aged 50-75 years who had undergone unilateral total knee arthroplasty and were 4-6 weeks post-operatively. Participants were required to have the cognitive capacity to understand the study instructions and to be able to walk independently.\n\nExclusion Criteria:\n\n* Individuals who had undergone bilateral total knee arthroplasty, those with advanced osteoarthritis in the other knee, those with neurological or orthopedic diseases affecting mobility, those who had undergone another major joint surgery within the last six months, and those with vestibular system disease were excluded from the study.","50 Years","75 Years",{"count":132,"type":21},75,"This observational study aims to investigate the relationships between proprioception, causes of kinesiophobia, sensory processing characteristics, and functional recovery in individuals undergoing gonarthrosis surgery. Postoperative functional recovery can be influenced by sensorimotor and psychological factors such as impaired proprioception, fear of movement, and changes in sensory processing. However, the interaction between these factors has not been sufficiently clarified. Participants will complete a sociodemographic and clinical information form, the Western Ontario and McMaster University Osteoarthritis Index (WOMAC), the Causes of Kinesiophobia Scale, and the Adolescent\u002FAdult Sensory Profile. Proprioception will be assessed using the Joint Position Perception Test.",[28],"2026-03-14",{"date":113,"type":33},{"date":138,"type":21},"2026-04-04",{"date":140,"type":21},"2026-05-15",{"name":142,"class":71},"Medipol University",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":22,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":72},"100629960","altered-joint-mechanics-and-biological-response-in-osteoarthritic-knees-100629960","NCT07481461","Altered Joint Mechanics and Biological Response in Osteoarthritic Knees.","Altered Joint Mechanics and Biological Response in Osteoarthritic Knees. A Study in Patients Undergoing Corrective Treatment for Knee Misalignment.","AMB-OK","Inclusion Criteria:\n\n* Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.\n* Chronic symptoms of (early) knee OA.\n* Misalignment of the lower limb and scheduled for HTO surgery (regardless of the HTO technique used (lateral or medial, closing or opening wedge)) or brace treatment.\n* Follow-up at UZ Leuven.\n\nExclusion Criteria:\n\n* Acute OA symptoms onset (previous knee injury)\n* Pregnant women\n* MRI checklist incomplete or failed\n* BMI \\> 30\n* Impaired vision or neurological condition that affect coordination and balance\n* Age \\\u003C18 (no minors will be included in the study)",{"count":81,"type":21},[83],"Osteoarthritis (OA) stands out as the most prevalent joint disease. It manifests as a progressive degradation of articular cartilage, new bone growth and often synovial tissue proliferation, resulting in pain and compromised joint functionality, ultimately leading to disability. Misalignment of the lower limb (varus or valgus knees) are recognised as a risk factor for osteoarthritis onset and progression. High tibial osteotomy (HTO) is a surgical technique that allows to shift the load from the affected area to other areas with intact cartilage. Similarly to HTO, braces realign the lower limb, without the need for surgical intervention. These corrective treatments are recommended for the youngest group of patients as it allows them to stay active, as opposed to Total Knee Replacement (TKR). Until today, the effects of braces and HTO on the subchondral bone microstructure and cartilage are not well understood. Investigating these aspects to better understand treatment failures is becoming more and more crucial because global prevalence of knee OA is expected to increase with the ageing of populations.",[28],"2026-03-13",{"date":113,"type":33},{"date":158,"type":21},"2026-04",{"date":160,"type":21},"2030-04",{"name":162,"class":71},"Universitaire Ziekenhuizen KU Leuven",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":22,"phases":174,"briefSummary":177,"conditions":178,"keywords":179,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":72},"100595711","phase-1-recombinant-human-growth-hormone-rhgh-for-knee-osteoarthritis-korr-100595711","NCT07036003","Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR)","Recombinant Human Growth Hormone (rHGH) for Knee Osteoarthritis (KORR): a Pilot, Randomized Placebo-controlled Trial","KORR","Inclusion Criteria:\n\n* Between 18 - 65 years old.\n* Diagnosis of isolated knee osteoarthritis for greater than 6 months.\n\nExclusion Criteria:\n\n* Previous or pending major intra-articular or reconstructive surgery to the involved knee, including femoral\u002Ftibial osteotomies, ligament repair\u002Freconstruction, or cartilage transplantation. Patients with remote (\\>1 year) diagnostic arthroscopy, arthroscopic debridement, meniscectomy, or meniscal repair may be allowed to participate at the investigators' discretion.\n* Previous major trauma (including fracture, dislocation, open injury) to the involved knee, or ipsilateral hip, knee, ankle, or hip. Patients with prior complete ligament tears will be excluded, patients with chronic partial thickness ligament tears or degenerative\u002Fcomplex meniscal tears (\\>6 months from injury) may be included at the investigators' discretion\n* Recent (less than 6 months) intra-articular injection into the involved knee.\n* High grade ligamentous knee injury.\n* Known allergy to recombinant human growth hormone (rHGH) or reconstitutive solutions.\n* BMI of less than 20 or greater than 35.\n* Documented history of growth disorder of bones or connective tissue, type 1 or 2 diabetes, myopathy, cancer, endocrine disorder, severe hypertension (SBP \\> 180) or rheumatologic disorder.\n* Pregnant or breastfeeding, or actively attempting to get pregnant.\n* Currently on hypoglycemic therapy, oral estrogen or glucocorticoid replacement therapy.\n* Would have difficulty with the self-injection schedule or other cognitive\u002F functional limitations.\n* Have taken creatine within 7 days before baseline. Potential participants will be given the option to pause their supplements and then re-screen if they are interested in the study,\n* Have taken anabolic steroids within 42 days (6 weeks) before baseline. Potential participants will be given the option to pause their supplements and then rescreen if they are interested in the study,\n* Vital signs or routine bloodwork outside of normal range.","65 Years",{"count":173,"type":21},34,[175,176],"PHASE1","PHASE2","The goal of this clinical trial is to see if people with knee osteoarthritis would be willing to comply and adhere to incorporating Recombinant Human Growth Hormone (rHGH), specifically Saizen Somatropin solution, into their treatment plan.\n\nParticipants will be asked to:\n\n* Self-inject the treatment solution (placebo or somatropin) into the abdominal or gluteal area once per day for a total of 6 weeks.\n* Complete questionnaires related to their knee pain and activities of daily living.\n* Provide blood tests.\n* Complete various measurements including: circumference of thigh, calf, and abdomen; strength of thigh and knee; range of motion of both knees; and gait analysis.",[57,28],[180,181,182,56,183],"Recombinant Human Growth Hormone","rHGH","Saizen","Knee OA","2026-03-12",{"date":186,"type":33},"2026-03-16",{"date":188,"type":33},"2025-10-31",{"date":190,"type":21},"2029-01",{"name":192,"class":71},"Dr. David Wasserstein",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":197,"acronym":198,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":17,"minAge":200,"maxAge":107,"enrollmentInfo":201,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":72},"100616689","individual-differences-in-gait-and-osteoarthritis-pain-100616689","NCT07308873","Individual Differences in Gait and Osteoarthritis Pain","INDIGO","Inclusion Criteria:\n\n* Knee pain for greater than 6 months.\n* Moderate-to-severe knee pain (\\>3\u002F10) due to osteoarthritis, as defined by American College of Rheumatology and EULAR diagnostic criteria, on \\>50% of days in the past month.\n* KL grade 2-4 indicating significant degenerative changes on knee X-ray.\n* 45-80 years old\n\nExclusion Criteria:\n\n* Inflammatory arthritis (e.g. rheumatoid arthritis).\n* More intense pain due to another chronic pain syndrome (e.g. fibromyalgia, hip osteoarthritis)\n* Significant pain or weakness in the lower extremities due to a neurological condition (e.g. lumbar radiculopathy, paresis due to stroke)\n* Acute pain that is more intense than knee osteoarthritis pain\n* Current routine use of more than 15 mg oral morphine equivalents per day (use of \\\u003C15 mg OME does not exclude the participant).\n* Recent new medication, exercise, behavioral, or complementary and integrative treatment started in the last month. Stable use of these treatments for greater than 1 month does not exclude the participant.\n* Recent intra-articular injection of steroid or other agent (greater than 1 month does not exclude the participant)\n* Recent knee radiofrequency ablation (greater than 3 months does not exclude the participant)\n* Recent knee arthroscopic surgery (greater than 3 months does not exclude the participant)\n* History of knee replacement or open knee surgery on the index knee, defined as the more painful knee on average over the last month.\n* Inability to walk or climb stairs without significant assistance (e.g. a one-person assist, use a wheel chair; however, the use of a cane does not exclude the participant).\n* Inability to participate in study procedures (e.g. cognitive impairment limiting ability to understand directions, inability to understand and read English)\n* Uncontrolled or unstable medical disorder preventing participation in study procedures\n* History of brain surgery\n* Tattoos on sensory testing sites\n* Pregnancy\n* Breastfeeding\n* Inability to under knee MRI scan due to incompatible devices or foreign bodies.","45 Years",{"count":202,"type":21},300,"The goal of this observational study is to look at inter-individual differences in knee osteoarthritis (OA) walking pain and performance. The main questions this study aims to answer are:\n\nWhy do some people with knee osteoarthritis have more severe disabling pain than others, even though the degenerative changes in their knees are similar?\n\nWhat are the factors that contribute to walking pain in people with knee osteoarthritis?\n\nParticipants will complete surveys, perform physical function tasks, get a knee X-ray and MRI, undergo non-invasive brain imaging, and undergo sensory testing.",[28,205,206],"Chronic Pain","Chronic Knee Pain","2026-01-27",{"date":209,"type":33},"2026-01-29",{"date":211,"type":33},"2026-01-07",{"date":213,"type":21},"2030-08-01",{"name":215,"class":71},"University of Pittsburgh",{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":4,"eligibilityCriteria":222,"healthyVolunteers":11,"sex":17,"minAge":200,"maxAge":130,"enrollmentInfo":223,"targetDuration":4,"studyType":22,"phases":225,"briefSummary":226,"conditions":227,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":72},"100586129","phase-2-the-effect-and-safety-of-anti-inflammatories-and-dextrose-prolotherapy-injections-in-treating-knee-osteoarthritis-100586129","NCT06911359","The Effect and Safety of Anti-inflammatories and Dextrose Prolotherapy Injections in Treating Knee Osteoarthritis","The Effect of Non-steroidal Anti-inflammatory Drug (NSAID) Use on the Efficacy of Dextrose Prolotherapy in the Treatment of Knee Osteoarthritis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Must be DoD Healthcare beneficiaries empaneled at DGMC\n* Adults aged 45-75 years with a clinical diagnosis of Knee OA (either unilateral or bilateral) based on clinical and radiographic criteria as defined by the American College of Rheumatology (Altman 1987)\n* Knee radiographs (within 2 years of start date) with Kellgren-Lawrence classification of 2-3\n* Moderate to severe Knee pain for at least 3 months defined as a score of ≥4 using the NPRS (0-10) in response to the question \"What is the average level of your left\u002F right knee pain in the past 3 months?\"\n* English speaking\n* Not pregnant\n* Not breastfeeding\n* No allergy to dextrose, lidocaine, or sulfite\n\nExclusion Criteria:\n\n* Previous knee replacement surgery\n* Previous meniscus repair\u002Fdebridement surgery or chondral replacement surgery\n* Any intra-articular injection including steroid, prolotherapy or platelet rich plasms within the previous 3 months\n* Significant effusion as defined by a ballotable patella\n* Pregnancy or breastfeeding\n* Current\u002Fongoing medical problems obtained from chart review contraindicating NSAID use to include chronic kidney disease stage II or higher, acute interstitial nephritis, coronary artery disease requiring percutaneous coronary intervention (PCI) or bypass surgery; Major Adverse Coronary Event (MACE), body mass index (BMI) ≥40, inflammatory arthropathy (gouty arthritis, psoriatic arthritis, or septic arthritis), history of GI bleed.\n* Non-English speaking\n* Allergy to dextrose, lidocaine, or sulfite",{"count":224,"type":21},68,[176],"Our purpose is to expand upon the results of the pilot study performed at David Grant Medical Center (DGMC) which showed that concomitant non-steroidal NSAID use in adults with knee osteoarthritis (OA) undergoing a three-shot dextrose prolotherapy (DPT) injection series did not negate the efficacy of DPT. Additionally, it showed that giving both treatments simultaneously is safe and efficacious. The small sample size and design of the pilot study limited the conclusions that can be drawn on the concomitant use of non-steroidal anti-inflammatory drugs (NSAIDs) during DPT treatment.\n\nThis is a double-blinded, randomized, controlled trial that includes a subject population of males and females between the ages of 45-75 years who are DoD beneficiaries empaneled at DGMC with a history of chronic, symptomatic knee osteoarthritis in one or both knees, that meet study criteria.\n\nParticipants will have study inclusion\u002Fexclusion and knee films (within the past 2 years) reviewed by a study investigator to confirm eligibility to participate in the study. Eligible participants will be consented then randomized into treatment groups (ibuprofen, placebo) by the pharmacy. Participants will provide a baseline assessment of pain and dysfunction using the Numeric Pain Rating Scale (NPRS) and Knee Injury and Osteoarthritis Outcome Score (KOOS) questionnaires. Participants will then have a series of three injections of 4mL of 25% dextrose mixed with 1% lidocaine into the knee under ultrasound guidance, performed at 0, 4 and 8 weeks (+\u002F- 1 week) in addition to a 7-day supply of the study drug (ibuprofen, placebo) at these time points. NPRS and KOOS scores will be collected at 0, 4, 8 and 12 weeks. During the study period, participants will be counseled to avoid oral analgesics (other than what has been prescribed for them as part of the study) including NSAIDs, acetaminophen, or opioids, in addition to other procedures to treat their knee pain to include other injections, acupuncture, physical therapy, and surgery.\n\nThe primary outcome is to determine the effect of concomitant oral ibuprofen vs. placebo use on intra-articular knee injections using hypertonic dextrose and the determine the short and long-term outcomes in each treatment group (ibuprofen, placebo) using the NPRS and KOOS questionnaires to assess pain and function.",[28],"2025-11-20",{"date":230,"type":33},"2025-11-24",{"date":232,"type":33},"2025-03-31",{"date":234,"type":21},"2026-12-31",{"name":236,"class":237},"David Grant U.S. Air Force Medical Center","FED",{"id":239,"slug":240,"hasResults":11,"nctId":241,"briefTitle":242,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":107,"enrollmentInfo":246,"targetDuration":4,"studyType":22,"phases":248,"briefSummary":249,"conditions":250,"keywords":251,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":263,"locationsCount":72},"100563577","knee-osteoarthritis-and-spa-therapy-100563577","NCT06617975","Knee Osteoarthritis and Spa Therapy","Evaluation of the Effectiveness of the Spa Therapy Program for Rheumatology at Santenay in Patients With Knee Osteoarthritis","SANTIAGO","Inclusion Criteria:\n\n* Knee osteoarthritis with Kellgren and Lawrence stage 2 to 4 evidenced by a knee X-ray examination in the past 3 years.\n* 100-normalized score of the WOMAC physical function subscale greater than or equal to 30.\n* Accepting a prescription for a balneotherapy program in the Rheumatology at Santenay spa as part of the management of their knee osteoarthritis issued by the investigator.\n* Signed inform consent.\n* With health insurance affiliation.\n\nExclusion Criteria:\n\n* Presented with balneotherapy contraindication or to certain adjuvant treatment techniques (balneation, hydrotherapy jets, massage): chronic infectious pathology, active cancer, decompensated cardiac, hepatic or renal insufficiency, \"open\" leg ulcer, immune deficiency, phlebitis, erysipelas or history of erysipelas, active thrombosis, behavioral disorders, etc.\n* Presented with chronic pain for reasons other than osteoarthritis: chronic inflammatory rheumatism (rheumatoid arthritis, ankylosing spondylitis, lupus, psoriatic arthritis) or fibromyalgia.\n* Having had spa treatment in the past 6 months whatever the indication or intra-articular corticosteroid injection within the previous 90 days or hyaluronic acid infiltration within the previous 6 months.\n* Having planned a spa treatment in another indication between inclusion and final visit.\n* Patient scheduled for knee osteoarthrosis-related surgery within the next 7 months.\n* Residing more than 30 kilometers from Santenay at the time of spa treatment. Women of childbearing potential who are not using effective contraception (estrogen\u002Fprogestin or progestin-only oral, vaginal, transdermal, injectable or subcutaneous) or who plan to discontinue contraception within the next 7 months.\n* Likely to be unable to comply with protocol or to attend visits, particularly in view of the duration of the research, or unable to read or understand French.\n* Regulatory reason (guardianship or already enrolled in a clinical trial).\n* Already included in a clinical trial or in the exclusion period of a clinical trial.",{"count":247,"type":21},80,[83],"The aim of this clinical trial is to assess the efficacy of the 18-day balneotherapy program (therapeutic indication: Rheumatology) in terms of functional incapacity and the disorders (pain, joint stiffness) induced by osteoarthritis of the knee, and thus improves patients\\' quality of life, in patients presented with knee osteoarthritis.\n\nThe French National Academy of Medicine encourages the re-use of RCT data when available. In this context, the current study is designed as a single-arm prospective study with external comparison using the propensity score. The Control group consists of the patients which were allocated to the Control group of reference randomized clinical trial (RCT) \"ANGELLO Study\" (NCT05819437). These patients received standard care for knee osteoarthritis, i.e., pain management and exercise recommendations.\n\nAll patients enrolled in the current study benefit of 18-day balneotherapy program (therapeutic indication: Rheumatology) with Mineral Water of Santenay (Burgundy, France), and examination with a practitioner at enrollment and 6 months after the beginning of spa treatment.",[56,28],[252,253,254,255,256],"Balneotherapy","Spa therapy","Rheumatology","Knee osteoarthritis","WOMAC","2025-08-04",{"date":259,"type":33},"2025-08-07",{"date":261,"type":33},"2024-10-14",{"date":234,"type":21},{"name":264,"class":40},"CEN Biotech",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":17,"minAge":273,"maxAge":107,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":276,"briefSummary":277,"conditions":278,"keywords":279,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":72},"100582119","phase-2-genicular-artery-embolization-for-reducing-pain-in-medically-refractory-symptomatic-knee-osteoarthritis-100582119","NCT06859164","Genicular Artery Embolization for Reducing Pain in Medically Refractory Symptomatic Knee Osteoarthritis","Genicular Artery Embolization for Reducing Pain in Symptomatic Knee Osteoarthritis: A Pilot Randomized Sham-Controlled Study","SHAM-PAIN","Inclusion Criteria:\n\n* Patients aged 40-80\n* Bilateral or unilateral knee pain attributed to osteoarthritis (treat the knee with greater pain-if equal, patient chooses)\n* Grade 2-4 osteoarthritis on standing weight-bearing knee radiographs per the Kellgren-Lawrence grading scale\n* Knee pain \\> 6 months, refractory to conservative non-operative management, and scored ≥ 4 on Visual Analog Scale (VAS) (e.g., rest, activity modification, weight control, bracing, supervised physical therapy, nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, oral opiates, intra-articular hyaluronic acid, PRP, stem cells, and\u002For oral\u002Finjectable corticosteroids)\n* Refusal of intra-articular corticosteroid injection\n\nExclusion Criteria:\n\n* Active malignancy\n* Active infection of the affected knee\n* Corticosteroid injection of the affected knee within 3 months of enrollment\n* Rheumatoid arthritis or other seronegative arthropathy\n* Previous surgery of the affected knee (e.g., meniscus repair, meniscectomy, anterior cruciate ligament (ACL)\u002Fposterior cruciate ligament (PCL) reconstruction, chondroplasty, microfracture, loose-body removal, synovectomy, lateral release, patellar\u002Fquadriceps tendon repair, total or partial knee replacement, osteotomy, cartilage transplant), except diagnostic arthroscopy\n* Grade 0-1 osteoarthritis per Kellgren-Lawrence grading scale of the affected knee\n* Pregnancy or expected pregnancy\n* GFR \\\u003C 60 mL\u002Fmin\u002F1.73 m²\n* Anaphylactic reaction to iodinated contrast\n* Moderate to severe pain in other ipsilateral lower-limb joints (ankle, hip) with VAS \\> 4\n* Body weight \\> 400 lbs (unsafe for angiography)\n* Peripheral arterial disease of the treated extremity (Rutherford Grade 2 or greater)\n* Type 1 diabetes mellitus\n* Long-acting corticosteroid use within 6 months (3 months for short-acting)\n* History or other evidence of acute kidney injury (AKI)\n* History of reaction to contrast media, bronchial asthma, or allergic disorders\n* History of hypersensitivity to gadolinium-based contrast agents (GBCAs)\n* Chronic widespread generalized pain \\>4 on VAS pain scale, including neuropathic pain\n* Major depressive disorder within 2 years before screening\n* Other severe psychiatric disorder (e.g., schizophrenia, bipolar disorder)\n* Suicide attempt or suicidal behavior within 30 days before screening\n* Diagnosis of fibromyalgia\n* Considering total knee replacement in the next year\n* Any other condition, unwillingness, or inability that, in the investigator's opinion, could jeopardize the subject's safety or protocol compliance","40 Years",{"count":275,"type":21},50,[176],"Genicular Artery Embolization for Reducing Pain in Symptomatic Knee Osteoarthritis: A Pilot Randomized Sham-Controlled Study (SHAM-PAIN) is a NIH-NIAMS funded project designed to assess enrollment feasibility and detect any differences between GAE and a similar sham intervention in reducing KOA-related pain at 3 months as measured by the Knee injury and Osteoarthritis Outcome Score (KOOS) pain subscore. Additionally, this study aims to determine the magnitude of difference in pain response between GAE and sham to adequately power a larger, more definitive randomized sham-controlled trial (RCT). The influence of psychosocial and psychocognitive factors, changes in analgesic use, and conditions of knee joint cartilage and effusion will similarly be explored to determine their impacts on perceived pain response to GAE.",[56,57,28],[280,281,282,283,284,48,285,286,287,288,289,290,291],"Osteoarthritis","Knee pain","MSK pain","Musculoskeletal Pain","Osteoarthritis of the knee","Genicular artery embolization","Geniculate artery embolization","MSK embolization","Musculoskeletal Embolization","Embolization","Musculoskeletal","Temporary Embolization","2025-05-14",{"date":294,"type":33},"2025-05-15",{"date":296,"type":33},"2025-05-01",{"date":298,"type":21},"2026-11-30",{"name":70,"class":71},{"id":301,"slug":302,"hasResults":11,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":4,"eligibilityCriteria":306,"healthyVolunteers":11,"sex":17,"minAge":273,"maxAge":171,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":309,"briefSummary":310,"conditions":311,"keywords":312,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":72},"100566674","effects-of-core-stabilization-exercises-versus-foot-ankle-strengthening-program-in-patients-with-knee-osteoarthritis-100566674","NCT06658249","Effects of Core Stabilization Exercises Versus Foot-Ankle Strengthening Program in Patients With Knee Osteoarthritis.","Comparative Effects of Core Stabilization Exercises Versus Foot-Ankle Strengthening Program on Pain, Physical Function and Quality of Life in Patients With Knee Osteoarthritis.","Inclusion Criteria:\n\n* Both genders of 40-65 years of age will include in this study.\n* Knee OA of grade 1-2.\n* Individuals with significant unilateral and bilateral knee osteoarthritis. symptoms and positive radio-graphical findings.\n* Difficulty in walking\u002Fstair climbing.\n\nExclusion Criteria:\n\n* Any history of knee fracture\u002F tumor\u002F infection and hip\u002Fknee surgery.\n* Total Knee Replacement patients.\n* Neurological disease.\n* Patient received physical therapy treatment from last 6 months.\n* Inflammatory Arthritis (Rheumatoid Arthritis)\n* Use of any intra-articular injections (steroid\u002F hyaluronic acid\u002F PRP.) from last 3-6 months.",{"count":308,"type":21},46,[83],"Knee osteoarthritis (OA) is also known as degenerative joint disease, is typically the result of wear and tear and progressive loss of articular cartilage. It is most common in the elder population. It results from functional disability and altered knee biomechanics. Risk factors of Knee OA include; older age, genetics and obesity, female gender. The aim of this study is to compare the effects of core stabilization exercises versus foot-ankle strengthening program on pain, physical function and quality of life in patients with knee osteoarthritis.",[28],[56,313,314,315],"Pain","Physical Function","Quality of Life","2024-11-12",{"date":318,"type":33},"2024-11-14",{"date":320,"type":33},"2024-01-04",{"date":322,"type":21},"2025-01-07",{"name":324,"class":71},"Riphah International University",{"id":326,"slug":327,"hasResults":11,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":4,"eligibilityCriteria":331,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":332,"enrollmentInfo":333,"targetDuration":4,"studyType":22,"phases":335,"briefSummary":336,"conditions":337,"keywords":339,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":72},"100561733","motor-sparing-techniques-genicular-nerve-radiofrequency-ablation-has-emerged-as-a-viable-alternative-to-conservative-therapy-and-total-knee-arthroplasty-100561733","NCT06594003","Motor Sparing Techniques, Genicular Nerve Radiofrequency Ablation Has Emerged As a Viable Alternative to Conservative Therapy and Total Knee Arthroplasty","Comparative Study Between Eight Versus Three Genicular Nerves Radiofrequency Ablation for Knee Denervation in Advanced Knee Osteoarthritis Using Ultrasound","Inclusion Criteria:\n\n* Age from 50-70 years.\n* Both sexes.\n* American Society of Anesthesiology (ASA) physical status I-III.\n* Patients with 3rd and 4th degree of KOA pain who undergo knee articular branch denervation via RF ablation.\n\nExclusion Criteria:\n\n* Deformities in knee.\n* Charcot joint (stiff Joint)\n* Acute knee injury\n* Previous ipsilateral total knee arthroplasty or radiofrequency denervation.\n* Instability of knee Joint.\n* Knee effusion \\& Baker's cyst . . Inability to assume a recumbent or semirecumbent position.","70 Years",{"count":334,"type":21},60,[83],"There has recently been considerable interest in the role of radiofrequency ablation (RFA) of the genicular nerves for KOA. In the majority of previous studies, ablation was done via a radiofrequency technique using either fluoroscopy or ultrasound for only three genicular nerves, whereas the knee joint is also supplied by a few other nerves (11, 12). Interestingly, neurolytic agents can also be used to ablate the nerves, and are readily available, less costly, and need less logistic support",[338],"Knee Osteoarthritis \\(OA\\)",[340,341,342,343],"knee","osteoarthritis","radiofrequency","genicular nerves","2024-09-10",{"date":346,"type":33},"2024-09-19",{"date":348,"type":21},"2024-10-01",{"date":350,"type":21},"2026-11-01",{"name":352,"class":71},"Assiut University"]